Create Account | Sign In: Author or Forum

Search Symptoms

Category: Neurology | Pharmacy | Journal

Back to Journal Articles

Parkinson’s Medications Tied to Impulse Control Disorders

Last Updated: June 21, 2018.

For patients with Parkinson's disease, dopamine agonist use is associated with incidence of impulse control disorders in a dose-effect relationship, according to a study published online June 20 in Neurology.

THURSDAY, June 21, 2018 (HealthDay News) -- For patients with Parkinson's disease (PD), dopamine agonist (DA) use is associated with incidence of impulse control disorders (ICDs) in a dose-effect relationship, according to a study published online June 20 in Neurology.

Jean-Christophe Corvol, M.D., from the Assistance Publique Hôpitaux de Paris, and colleagues used data from a multicenter longitudinal cohort of consecutive patients with PD with no more than five years of disease duration at baseline. Patients were followed up annually up to five years to examine the longitudinal dose-effect correlation between dopamine replacement therapy and ICDs. During face-to-face semi-structured interviews with movement disorder specialists, ICDs were evaluated.

The researchers found that 86.6 percent of the 411 patients took a DA at least once since disease onset. The five-year cumulative incidence of ICDs was 46.1 percent in 306 patients without ICDs at baseline (DA ever-users, 51.5 percent; DA never users, 12.4 percent). There was an increase in the prevalence of ICDs from 19.7 percent at baseline to 32.8 percent after five years. There was a correlation for ICDs with ever DA use (prevalence ratio, 4.23). There were independent associations for lifetime average daily dose and duration of treatment with ICDs, with significant dose-effect relationships. After discontinuation of DA, ICDs progressively resolved.

"ICDs were strongly associated with DA use with a dose-effect relationship; both increasing duration and dose were associated with ICDs," the authors write. "ICDs progressively resolved after DA discontinuation."

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)


Previous: ACA Provisions Tied to Change in Profile of Frequent ER Users Next: Rate of Death Up in Year After Non-Fatal Opioid Overdose

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion: